ARCTURUS THERAPEUTICS HOLDINGS INC. Form 8-K (Jan. 11, 2022)

Summary

Current report on Form 8-K of Arcturus Therapeutics Holdings Inc., date of report January 11, 2022, filed under Item 7.01, Regulation FD Disclosure. It states that the company commenced submission of regulatory documents to the Ministry of Health in Vietnam in December 2021 for an Emergency Use Authorization application for ARCT-154, described as a next generation, self-amplifying mRNA vaccine candidate against COVID-19. The report says the company plans to complete the application in the first quarter of 2022, assuming positive data. The information is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. The signature block shows /s/ Joseph E. Payne, dated January 11, 2022.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 11, 2022

ARCTURUS THERAPEUTICS
HOLDINGS INC.

(Exact name of registrant as specified in its
charter)

Delaware | 001-38942 | 32-0595345
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.)

10628 Science Center Drive , Suite 250

San Diego , California 92121

(Address of principal executive offices)

Registrant’s telephone number, including
area code: (858) 900-2660

(Former name or former address, if changed since
last report)

Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common stock, par value $0.001 per share | ARCT | The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

Arcturus Therapeutics Holdings Inc. commenced the submission of regulatory
documents to the Ministry of Health in Vietnam in December 2021 with respect to an Emergency Use Authorization application for ARCT-154
(its next generation, self-amplifying mRNA vaccine candidate against COVID-19), and plans to complete an Emergency Use Authorization application
in the first quarter of 2022, assuming positive data.

The information in this Item 7.01 to this Current Report on Form 8-K
shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in
any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference
in such a filing.

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K contain forward-looking statements
that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform
Act of 1995. Any statements, other than statements of historical fact included in this Current Report on Form 8-K, are forward-looking
statements, including those regarding plans to complete an Emergency Use Authorization application in Vietnam for ARCT-154 in the first
quarter of 2022. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed
in any forward-looking statements such as the foregoing and you should not place undue reliance on such forward-looking statements. These
statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties, and other factors
that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different
from those anticipated by the forward-looking statements, including those discussed under the heading "Risk Factors" in Arcturus’
most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in subsequent filings with, or submissions to,
the SEC, which are available on the SEC’s website at www.sec.gov. Except as otherwise required by law, Arcturus disclaims any intention
or obligation to update or revise any forward-looking statements made in this Current Report on Form 8-K, which speak only as of the date
they were made, whether as a result of new information, future events or circumstances or otherwise.

The statements made in this Current Report on Form 8-K speak only as
of the date stated herein, and subsequent events and developments may cause the Company’s expectations and beliefs to change. While
the Company may elect to update these forward-looking statements publicly at some point in the future, the Company specifically disclaims
any obligation to do so, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking
statements should not be relied upon as representing the Company’s views as of any date after the date stated herein.

SIGNATURES

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Arcturus Therapeutics Holdings Inc.
Date: January 11, 2022
By: | /s/ Joseph E. Payne
Name: | Joseph E. Payne
Title: | Chief Executive Officer

File and source

File

SEC_ARCT_8-K_filed2022-01-11_0001193805-22-000036.htm

Size

23,875 bytes

SHA-256

cec1a6c4b823a76f690df7134412785554e2dfda4dca5710404e1a8844008df8

Our copy

SEC_ARCT_8-K_filed2022-01-11_0001193805-22-000036.htm

Original

www.sec.gov